TY - JOUR
T1 - Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer
AU - Jacobs, Elizabeth T.
AU - Giuliano, Anna R.
AU - Martínez, María Elena
AU - Hollis, Bruce W.
AU - Reid, Mary E.
AU - Marshall, James R.
N1 - Funding Information:
Dr. Jacobs was supported by an R-25 post-doctoral cancer prevention fellowship (CA-78447) from the National Cancer Institute.
PY - 2004/5
Y1 - 2004/5
N2 - In the US, prostate cancer (PCa) has the highest incidence rate of all cancers in males, with few known modifiable risk factors. Some studies support an association between the Vitamin D metabolites, 1,25-dihydroxyvitamin D (1α,25(OH)2D3) and/or 25-hydroxyvitamin D (25(OH)D3), and prostate cancer, while others have yielded conflicting results. 1α,25(OH)2D3 has anti-proliferative and pro-differentiating effects in prostate cancer cell lines, and levels of circulating 25(OH)D3 may be important as PCa cells possess 1-α-hydroxylase activity. Using a nested case-control design, we evaluated whether plasma levels of 25(OH)D3 and 1α,25(OH)2D3 were associated with prostate cancer risk in participants from the Nutritional Prevention of Cancer (NPC) trial. With 83 cases and 166 matched controls, we calculated the adjusted odds ratios for increasing plasma levels of 25(OH)D3 and 1α,25(OH) 2D3. Compared to the lowest tertile of plasma 25(OH)D 3 levels, the adjusted odds ratios were 1.71 (0.68-4.34) and 0.75 (0.29-1.91); the corresponding odds ratios for 1α,25(OH)2D 3 were 1.44 (0.59-3.52) and 1.06 (0.42-2.66). Given the pivotal effects of the Vitamin D receptor on gene transcription, it is likely that the anti-carcinogenic effects of Vitamin D that have previously been described are related to the activity and expression of the Vitamin D receptor and should be investigated further.
AB - In the US, prostate cancer (PCa) has the highest incidence rate of all cancers in males, with few known modifiable risk factors. Some studies support an association between the Vitamin D metabolites, 1,25-dihydroxyvitamin D (1α,25(OH)2D3) and/or 25-hydroxyvitamin D (25(OH)D3), and prostate cancer, while others have yielded conflicting results. 1α,25(OH)2D3 has anti-proliferative and pro-differentiating effects in prostate cancer cell lines, and levels of circulating 25(OH)D3 may be important as PCa cells possess 1-α-hydroxylase activity. Using a nested case-control design, we evaluated whether plasma levels of 25(OH)D3 and 1α,25(OH)2D3 were associated with prostate cancer risk in participants from the Nutritional Prevention of Cancer (NPC) trial. With 83 cases and 166 matched controls, we calculated the adjusted odds ratios for increasing plasma levels of 25(OH)D3 and 1α,25(OH) 2D3. Compared to the lowest tertile of plasma 25(OH)D 3 levels, the adjusted odds ratios were 1.71 (0.68-4.34) and 0.75 (0.29-1.91); the corresponding odds ratios for 1α,25(OH)2D 3 were 1.44 (0.59-3.52) and 1.06 (0.42-2.66). Given the pivotal effects of the Vitamin D receptor on gene transcription, it is likely that the anti-carcinogenic effects of Vitamin D that have previously been described are related to the activity and expression of the Vitamin D receptor and should be investigated further.
KW - 1,25-Dihydroxyvitamin D
KW - 25-Hydroxyvitamin D
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=3042592220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042592220&partnerID=8YFLogxK
U2 - 10.1016/j.jsbmb.2004.03.063
DO - 10.1016/j.jsbmb.2004.03.063
M3 - Article
C2 - 15225833
AN - SCOPUS:3042592220
SN - 0960-0760
VL - 89-90
SP - 533
EP - 537
JO - Journal of Steroid Biochemistry and Molecular Biology
JF - Journal of Steroid Biochemistry and Molecular Biology
ER -